MIRM News and Press, Mirum Pharmaceuticals Inc.

Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only therapy indicated for CTX in the US Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the submission of a new drug application (ND...

2024-06-27 16:48:49 ET Summary The small biotech sector has badly underperformed the major market indices so far in 2024. However, that could change as the Federal Reserve cuts interest rates and/or M&A deal volume picks up across the industry. Today, we highlight three sm...

2024-06-23 05:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-17 16:15:02 ET Evercore ISI analyst issues OUTPERFORM recommendation for MIRM on June 17, 2024 03:27PM ET. The previous analyst recommendation was Outperform. MIRM was trading at $32.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-17 13:30:03 ET H.C. Wainwright analyst issues BUY recommendation for MIRM on June 17, 2024 11:32AM ET. The previous analyst recommendation was Buy. MIRM was trading at $30.99 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

2024-06-17 13:26:03 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value Mirum Pharmaceuticals GAAP EPS of -$0.54 misses by $0.14, reve...

2024-06-17 13:00:06 ET Ed Arce from H.C. Wainwright issued a price target of $66.00 for MIRM on 2024-06-17 11:32:00. The adjusted price target was set to $66.00. At the time of the announcement, MIRM was trading at $30.99. The overall price target consensus is at $50.67 ...

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus - VISTAS PSC interim analysis exceeds efficacy threshold for study continuation - Mirum to host conference call to discuss a...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary scle...

2024-06-13 06:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...